Northwest Biotherapeutics closes registered direct placement of $12.6M

Download PDF Copy

Editorial Checklist

Reviewed

Northwest BiotherapeuticsDec 26 2015

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of its previously-announced registered direct placement with healthcare focused institutional investors, for gross proceeds of $12.6 million on the terms previously announced.

H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction.

Source:

Northwest Biotherapeutics

Posted in: Business / Finance

Tags: Biotechnology, Biotherapeutics, Brain, Brain Cancer, Cancer, Cell, Clinical Trial, Dendritic Cell, Glioblastoma, Glioblastoma Multiforme, Gliomas, Healthcare, Hospital, Immune System, Immunotherapy, Ovarian Cancer, Prostate Cancer, Tumor

Comments (0)

Download PDF Copy

Suggested Reading

Survey reveals strong public desire for notification about AI use in healthcare

Survey reveals strong public desire for notification about AI use in healthcare

Lipid imbalances hold the key to chronic inflammation in colon cancer

Lipid imbalances hold the key to chronic inflammation in colon cancer

Study unveils key mechanism behind prostate cancer's uncontrolled growth

Study unveils key mechanism behind prostate cancer's uncontrolled growth

He went in for a colonoscopy. The hospital charged $19,000 for two.

He went in for a colonoscopy. The hospital charged $19,000 for two.

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Study links Western diet to chronic inflammation and colorectal cancer growth

Study links Western diet to chronic inflammation and colorectal cancer growth

Accelerated aging linked to early-onset colorectal cancer, study shows

Accelerated aging linked to early-onset colorectal cancer, study shows

Metastatic breast cancer rates surge across U.S. women, exposing disparities and pandemic impacts

Metastatic breast cancer rates surge across U.S. women, exposing disparities and pandemic impacts

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer